Gemini Therapeutics, Inc. — Form D
Gemini Therapeutics, Inc. of CAMBRIDGE, MA, a company, filed a Form D exempt-offering notice with the SEC on 2016-05-02. The offering totals $2.0M, of which $2.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2016-05-02
- Form: D
- Accession: 0001672981-16-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $2.0M
- Amount sold: $2.0M
- Investors: 4
- Date of first sale: 2016-04-19
- Security types: equity, debt
- Revenue range: Decline to Disclose
- SEC file number: 021-262383
Issuer
- Name: Gemini Therapeutics, Inc.
- CIK: 0001672981
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2015
- Address: 36 IRVING STREET, #3, CAMBRIDGE, MA, 02138
- Phone: 617 678 3113
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| JEAN GEORGE | Director | LEXINGTON, MA |
| CARL GORDON | Director | SAN DIEGO, CA |
| James McLaughlin | Director | Cambridge, MA |
| Jason Rhodes | Director | Cambridge, MA |
| James McLaughlin | Executive Officer | Cambridge, MA |
More